| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2,941.0 | 2,681.0 |
| Profit before tax | 597.0 | 218.0 |
| Net income | 436.0 | 179.0 |
| EPS (diluted, $ a share) | $1.15 | $0.48 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +143.6% |
|---|---|
| Revenue, year on year | +9.7% |
| Operating margin | 33.4% |
10-Q filed with the SEC, NYSE: BHC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bausch Health Companies Inc.: key numbers
- Share price
- $8.47Close, Nov 17
- Market cap
- $3.17B
- Shares outstanding
- 374.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bausch Health Companies Inc.
All →Bausch Health Companies Financial Results
Bausch Health reported third quarter 2026 consolidated revenues of $2.94 billion, a 10% increase over the prior year, and GAAP net income of $446 million. The company achieved a milestone with quarterly Adjusted EBITDA (excluding Bausch + Lomb) exceeding $1 billion for the first time and raised its full-year 2026 guidance across revenue and EBITDA metrics.
- Term
- Q3 2026
“Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation.”
Thomas J. Appio, Chief Executive Officer, Bausch Health